Glenmark Pharmaceuticals Limited has approved the transfer of its Nebulizer brands and IP portfolio to Glenmark Healthcare Limited (GHL), a wholly owned subsidiary, for a cash consideration of ₹223 Cr. The Board of Directors sanctioned the transaction on May 29, 2026, to enable sharper strategic focus and greater operational agility within the respiratory segment. This move is designed to scale the Nebulizer business, which is registering robust growth across India and Emerging Markets.

The transfer is expected to be carried out based on an Independent Valuer report, with the agreement for sale scheduled to be entered into on June 1, 2026. The company anticipates completing the disposal on or before June 30, 2026. GHL is currently establishing a new dedicated Nebulizers manufacturing facility to house these products, which will include the world's first nebulized triple therapy for Chronic Obstructive Pulmonary Disease (COPD).

Financial disclosures for the unit indicate that for the nine months ended December 31, 2025, the Nebulizer business recorded revenue of ₹71.6 Cr. This figure represented approximately 1.3% of the Company's standalone revenue for the corresponding period. As of March 31, 2026, the net worth of the GHL business was reported to be about negative ₹9.9 Cr.

The transaction qualifies as a related party transaction since GHL is a wholly owned subsidiary of Glenmark Pharmaceuticals Limited. The company confirmed that the deal is being conducted at arm's length. There will be no change in the shareholding pattern of the listed entity as a result of this transfer. GHL is engaged in the manufacturing and marketing of pharmaceutical products, with its registered office located in Andheri (East), Mumbai.

Key Transaction Details

The rationale behind the transfer centers on long-term value creation for stakeholders. By consolidating the Nebulizer portfolio under GHL, Glenmark aims to strengthen its leadership in respiratory innovation. The subsidiary will manage a portfolio of innovative nebulizers, reinforcing the company's commitment to providing advanced, affordable, and accessible solutions for patients.

Glenmark Pharmaceuticals has scheduled an earnings call to discuss the financial results for the quarter and year ended March 31, 2026. The conference call is set to take place on Monday, June 1, 2026, from 8:30 a.m. to 9:30 a.m. IST. This announcement follows the company's board meeting held on May 29, 2026, where the board considered the audited standalone and consolidated financial results for the period.

Earnings Call Details

The management will address analysts and investors regarding the company's performance for Q4 and the full fiscal year FY26. Participants can join the discussion using the provided dial-in numbers. The recording of the call will be made available on the company's official website within 24 hours of the conclusion of the session.

Board Meeting Outcome

During the meeting on May 29, the board approved the financial results for the quarter and year ended March 31, 2026. Additionally, the board deliberated on recommending a dividend on equity shares for the fiscal year ended March 31, 2026. The trading window for directors and designated persons, which was closed from March 31, 2026, to May 31, 2026, will reopen in accordance with regulatory norms.

Investors seeking further clarification regarding the earnings call can contact Utkarsh Gandhi via email at utkarsh.gandhi3@glenmarkpharma.com or by phone at +91 22 4018 9232.